arrow
M

Marie Robin

Université de Paris
H指数:60
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Auto-immune diseases associated with myelodysplastic syndrome and chronic myelomonocytic leukemia do not impact allogenic transplantation outcomes

与骨髓增生异常综合征和慢性骨髓单核细胞白血病相关的自身免疫性疾病不影响异基因移植结局

2026-10-060
PRE
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party

异基因造血细胞移植治疗年轻成人骨髓增生异常综合征:代表EBMT慢性恶性疾病工作组进行的回顾性研究

2026-09-300
OA
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS

在AML和MDS的RIC匹配供者PBSC移植中,使用PTCy、ATG、PTCy+ATG或无体内T细胞清除的GVHD预防

2026-09-120
PRE
Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone—a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT

异基因造血细胞移植治疗伴有阵发性睡眠性血红蛋白尿克隆异常的骨髓增生异常综合征——欧洲血液和骨髓移植学会慢性恶性病和重症再生障碍性贫血工作组代为研究

2026-08-130
PRE
ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC

ALLOPLUS:人类免疫缺陷病毒感染者儿童和成人的同种异基因造血干细胞移植,SFGM-TC的回顾性研究

2026-07-060
PRE
Upfront alemtuzumab-based MUD HSCT in childhood aplastic anemia: excellent survival and GRFS, but immune challenges persist

upfront 阿仑珠单抗为基础的无关供者造血干细胞移植在儿童再生障碍性贫血中的应用:极佳的生存率和无复发生存,但免疫挑战持续存在

2026-05-110
PRE
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee

定义异基因造血细胞移植后骨髓增生异常/骨髓增生性肿瘤的缓解和复发,并优化移植结果:EBMT实践协调与指南委员会的建议

2026-04-010
PRE
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm

一项由EBMT慢性恶性疾病工作组代表进行的关于异基因造血细胞移植治疗骨髓纤维化的欧洲调查:聚焦于JAK抑制剂的“真实世界”经验、脾肿大管理以及移植算法中的新型药物

2025-12-240
OAAI
Total-body irradiation-based versus chemotherapy alone as myeloablative conditioning regimen prior to hematopoietic allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia: a multi-institutional study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

全身照射为基础与单纯化疗作为成人急性淋巴细胞白血病患者造血同种异基因干细胞移植前骨髓清除性预处理方案:一项来自法语区骨髓移植与细胞治疗学会(SFGM-TC)的多中心研究

2025-10-220
PRE
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

移植预处理强度(TCI)评分可预测骨髓纤维化患者的allo-HCT结局:EBMT慢性恶性疾病工作组的研究

2025-10-150
OA
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability

低风险MDS患者的移植治疗:一项基于供者可及性的前瞻性II期试验

2025-10-100
OAAI
Predicting cardiovascular events in allogeneic haematopoietic stem cell transplant recipients

预测异基因造血干细胞移植受者的心血管事件

2025-10-010
PRE
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

欧洲接受CAR T细胞疗法治疗的血液恶性肿瘤患者的患者报告结局

2025-09-260
OAAI
Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies

同种异基因造血干细胞移植在种系DDX41突变伴髓系恶性肿瘤患者中的应用

2025-09-110
OAAI
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

供者类型对骨髓纤维化患者异基因造血细胞移植后结局的影响:欧洲血液和骨髓移植学会慢性恶性疾病工作组的研究

2025-08-290
OAAI
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT

Conditioning强度在年龄≥50岁接受异基因造血细胞移植(allo-HCT)的骨髓增生异常综合征患者中的研究:代表EBMT慢性恶性疾病工作组的研究

2025-08-290
OAAI